Search results for "ORPHAN DRUG|Designated|Treatment of basal cell carcinoma nevus syndrome (BCCNS)" in comments (approximate match)
Showing 1 - 1 of 1 results
Rostaporfin (SnET2, Purlytin, REM-001), a second generation photosensitizer drug, that was developed as part of Miravant's PhotoPoint photodynamic therapy (PDT) program, for the potential treatment of wet age-related macular degeneration (AMD). It wa...